Biotechnology | Disease | FDA
Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis
On Aug. 27, 2026, Roivant announced that the U.S. Food and Drug Administration (FDA) has approved LISRAYA™ (brepocitinib)…